The prevalence of menopausal symptoms in a community in Singapore

Chim, Harvey; Tan, Bee Huat; Ang, Chia Chun; Chew, Ee Ming; Chong, Yap Seng; Saw, Seang Mei

doi:10.1016/s0378-5122(01)00299-7

Cited by 140 publications

(122 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[3] Studies conducted at various other countries showed mean age of menopause slightly higher as compared to Indian studies, Malaysia (51.2 years), Thailand (48.7 years), and Singapore (49.1 years). [12][13][14] Menopause-related symptoms assessed by present study were quite similar to other studies. In the study conducted at Bihar [15] using same rating scale, 112 (40.1%) women found to have episodes of hot flashes, sweating, and/or night sweats in the preceding 4 weeks.…”

Section: Discussionsupporting

confidence: 89%

Current scenario of menopause-related symptoms using menopause rating scale among middle-aged women of Western India: A cross-sectional study

Patel¹,

Shah²,

Kamani³

et al. 2017

Int J Med Sci Public Health

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 89%

Current scenario of menopause-related symptoms using menopause rating scale among middle-aged women of Western India: A cross-sectional study

Patel¹,

Shah²,

Kamani³

et al. 2017

Int J Med Sci Public Health

View full text Add to dashboard Cite

“…This finding is consistent with the low incidence of hot flushes seen with raloxifene in postmenopausal Japanese women (11) and reports that Asian women are generally less likely to report hot flushes and other menopausal symptoms than white women. (18)(19)(20)(21) Additionally, there were no reports of venous thromboembolic events. The numbers of cardiovascular and cerebrovascular AEs were low and similarly distributed among treatment groups.…”

Section: Discussionmentioning

confidence: 99%

Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal japanese women with osteoporosis

Itabashi¹,

Chines

Miki

et al. 2010

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

This randomized, double-blind, placebo-controlled, dose-response late phase 2 study evaluated the efficacy and safety of bazedoxifene in postmenopausal Japanese women 85 years of age or younger with osteoporosis. Eligible subjects received daily treatment with oral doses of bazedoxifene 20 or 40 mg or placebo for 2 years. Efficacy assessments included bone mineral density (BMD) at the lumbar spine and other skeletal sites, bone turnover marker levels, lipid parameters, and incidence of new fractures. Of 429 randomized subjects, 387 were evaluable for efficacy, and 423 were included in the safety analyses (mean age, 64 years). At 2 years, the mean percent changes from baseline in lumbar spine BMD were significantly greater with bazedoxifene 20 and 40 mg (2.43% and 2.74%, respectively) than with placebo (À0.65%, p < .001 for both). Both bazedoxifene doses significantly improved BMD at the total hip, femoral neck, and greater trochanter compared with placebo ( p < .001 for all). Decreases in bone turnover markers were observed with bazedoxifene 20 and 40 mg as early as 12 weeks ( p < .05 for all) and were sustained throughout the study. Total and low-density lipoprotein cholesterol levels were significantly decreased from baseline with both bazedoxifene doses compared with placebo ( p < .05 for all). Incidences of new vertebral and nonvertebral fractures were similar among the bazedoxifene and placebo groups. Overall, the incidence of adverse events with bazedoxifene 20 and 40 mg was similar to that with placebo. Bazedoxifene significantly improved BMD, reduced bone turnover, and was well tolerated in postmenopausal Japanese women with osteoporosis. ß

show abstract

“…The size of our cohort allowed us to analyze specifically women who experienced menopause during follow-up, resulting in a restriction of our population, but diminishing the potential for a recall bias without creating any selection bias, and concentrating our analysis on critical periods. Most previous studies focused on the prevalence of menopausal symptoms [2][3][4][5][6]8,9,12], which reflects both their onset and their duration in an indistinguishable manner. Moreover, previous studies on menopausal symptoms either included or excluded women on HRT [3,7].…”

Section: Discussionmentioning

confidence: 99%

“…These may occur before or after the onset of menopause. Studies on the prevalence of menopausal symptoms during menopausal transition have reported that these were more likely to be experienced in late menopausal transition and in early postmenopause [2][3][4][5][6][7][8][9][10][11][12]. However, the main methodologic issues that limit inferences from epidemiologic studies of the menopausal transition are lack of longitudinal studies and short follow-up [5,13].…”

Section: Introductionmentioning

confidence: 99%

Risk of onset of menopausal symptoms in periods surrounding menopause

et al. 2007

View full text Add to dashboard Cite

To cite this version:Séverine Sabia, Agnès Fournier, Sylvie Mesrine, Marie-Christine Boutron-Ruault, Françoise ClavelChapelon. Risk of onset of menopausal symptoms in periods surrounding menopause.. Maturitas, Elsevier, 2007, 58 (4) AbstractObjective: To assess the risk of onset of menopausal symptoms at different periods surrounding menopause, and variations in this risk according to age at menopause and type of menopause. Methods: We analyzed the 27,897 women participating in the French E3N cohort study who reached menopause during a 10-year follow-up period (1990)(1991)(1992)(1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000). Self-administered questionnaires, completed approximately every 24 months, included questions on the use of hormonal treatments, reproductive factors, personal history of a variety of diseases and the occurrence of personal medical events, including menopausal symptoms. Hazard ratios (HRs) were computed from multivariate Cox models. Results: When compared to the year preceding menopause, the risk of onset of menopausal symptoms was higher in the year following menopause (for natural menopause (n = 25,753), HR= 1.22, 95% confidence interval: 1.17, 1.27, and for artificial menopause (n = 2,147), HR= 2.21, 95% CI: 1.93, 2.52). More than one year prior to menopause and more than one year after, HRs were significantly below unity. The risk of onset of menopausal symptoms in the year following menopause was 1.47-fold (95% CI: 1.31, 1.64) higher in women having undergone an artificial menopause than in women who had had a natural menopause. In other periods, the risks did not differ significantly according to type of menopause. Those who experienced menopausal symptoms in the 1-5 year period following menopause were more likely to have reached their menopause before 51 years. Conclusions:The risk of onset of menopausal symptoms at different time periods surrounding menopause varies according to both type of menopause and age at menopause.

show abstract

The prevalence of menopausal symptoms in a community in Singapore

Cited by 140 publications

References 31 publications

Current scenario of menopause-related symptoms using menopause rating scale among middle-aged women of Western India: A cross-sectional study

Current scenario of menopause-related symptoms using menopause rating scale among middle-aged women of Western India: A cross-sectional study

Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal japanese women with osteoporosis

Risk of onset of menopausal symptoms in periods surrounding menopause

Contact Info

Product

Resources

About